According to Sarepta Therapeutics
's latest financial reports the company has a price-to-book ratio of 14.3.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 10.5 | -64.47% |
2022-12-31 | 29.5 | 249.71% |
2021-12-31 | 8.45 | -52.16% |
2020-12-31 | 17.7 | 48.95% |
2019-12-31 | 11.9 | 57.82% |
2018-12-31 | 7.51 | 64.9% |
2017-12-31 | 4.56 | 2.45% |
2016-12-31 | 4.45 | -51.91% |
2015-12-31 | 9.25 | 283.15% |
2014-12-31 | 2.41 | -22.41% |
2013-12-31 | 3.11 | -52.96% |
2012-12-31 | 6.61 | 102.84% |
2011-12-31 | 3.26 | -103.86% |
2010-12-31 | -84.6 | -1338.5% |
2009-12-31 | 6.83 | 129.38% |
2008-12-31 | 2.98 | -13.59% |
2007-12-31 | 3.44 | -23.19% |
2006-12-31 | 4.48 | 36.28% |
2005-12-31 | 3.29 | 1.78% |
2004-12-31 | 3.23 | 0.02% |
2003-12-31 | 3.23 | -42.85% |
2002-12-31 | 5.66 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | 3.58 | -74.93% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -2.65 | -118.54% | ๐บ๐ธ USA |
Novavax NVAX | -0.7890 | -105.53% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -83.0 | -681.61% | ๐บ๐ธ USA |
Insmed INSM | -11.1 | -177.89% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | -1.92 | -113.45% | ๐บ๐ธ USA |
Avidity Biosciences RNA | 3.80 | -73.38% | ๐บ๐ธ USA |